On the public citation graph

The Effect of Centralised Procurement on Pharmaceutical Marketing and Innovation: Evidence from China

https://doi.org/10.2139/ssrn.4755499
0 signed · 47 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/978-1-349-15486-9_13openalex-extracted
Economic Welfare and the Allocation of Resources for Invention
inferredcites →https://doi.org/10.1007/978-3-642-51565-1_54openalex-extracted
Optimal Advertising Policy Under Dynamic Conditions
inferredcites →https://doi.org/10.1007/978-3-662-05858-9_30openalex-extracted
Closed-loop equilibrium in a multi-stage innovation race
inferredcites →https://doi.org/10.1007/s00199-002-0310-yopenalex-extracted
Closed-loop equilibrium in a multi-stage innovation race
inferredcites →https://doi.org/10.1016/0014-2921(83)90087-9openalex-extracted
Preemption, leapfrogging and competition in patent races
inferredcites →https://doi.org/10.1016/0047-2727(75)90017-1openalex-extracted
The economics of corruption
inferredcites →https://doi.org/10.1016/bs.hesind.2021.11.013openalex-extracted
Innovation: market failures and public policies
inferredcites →https://doi.org/10.1016/j.jdeveco.2013.02.010openalex-extracted
Corruption and product market competition: An empirical investigation
inferredcites →https://doi.org/10.1016/j.jeconom.2020.12.001openalex-extracted
Difference-in-Differences with multiple time periods
inferredcites →https://doi.org/10.1016/j.jeconom.2022.07.003openalex-extracted
Nonparametric difference-in-differences in repeated cross-sections with continuous treatments
inferredcites →https://doi.org/10.1016/j.jhealeco.2013.01.001openalex-extracted
Pharmaceutical advertising and Medicare Part D
inferredcites →https://doi.org/10.1016/j.jhealeco.2013.03.007openalex-extracted
Demand for smokeless tobacco: Role of advertising
inferredcites →https://doi.org/10.1016/j.jhealeco.2020.102332openalex-extracted
Drug insurance and the strategic behavior of drug manufacturers: Evergreening and generic entry after Medicare Part D
inferredcites →https://doi.org/10.1016/j.jpubeco.2008.09.001openalex-extracted
Political decentralization and corruption: Evidence from around the world
inferredcites →https://doi.org/10.1016/j.jpubeco.2012.10.003openalex-extracted
Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development
inferredcites →https://doi.org/10.1016/s0169-7218(10)01004-xopenalex-extracted
Fifty Years of Empirical Studies of Innovative Activity and Performance
inferredcites →https://doi.org/10.1017/s0007123402000066openalex-extracted
Sources of Corruption: A Cross-Country Study
inferredcites →https://doi.org/10.1056/nejmp048357openalex-extracted
To Inform or Persuade? Direct-to-Consumer Advertising of Prescription Drugs
inferredcites →https://doi.org/10.1056/nejmsa070502openalex-extracted
A Decade of Direct-to-Consumer Advertising of Prescription Drugs
inferredcites →https://doi.org/10.1086/695475openalex-extracted
Positive Spillovers and Free Riding in Advertising of Prescription Pharmaceuticals: The Case of Antidepressants
inferredcites →https://doi.org/10.1086/712506openalex-extracted
Killer Acquisitions
inferredcites →https://doi.org/10.1093/heapol/czad015openalex-extracted
Understanding medical corruption in China: a mixed-methods study
inferredcites →https://doi.org/10.1111/1756-2171.12113openalex-extracted
Market size and pharmaceutical innovation
inferredcites →https://doi.org/10.1111/ecin.12378openalex-extracted
CORRUPTION, PRODUCT MARKET COMPETITION, AND INSTITUTIONAL QUALITY: EMPIRICAL EVIDENCE FROM THE U.S. STATES
inferredcites →https://doi.org/10.1111/j.1465-7295.2007.00107.xopenalex-extracted
WHAT DETERMINES CORRUPTION? INTERNATIONAL EVIDENCE FROM MICRODATA
inferredcites →https://doi.org/10.1111/j.1756-2171.2006.tb00033.xopenalex-extracted
The role of firm characteristics in pharmaceutical product launches
inferredcites →https://doi.org/10.1111/joes.12198openalex-extracted
CAUSES AND EFFECTS OF CORRUPTION: WHAT HAS PAST DECADE'S EMPIRICAL RESEARCH TAUGHT US? A SURVEY
inferredcites →https://doi.org/10.1136/bmj-2022-071710openalex-extracted
High drug prices are not justified by industry’s spending on research and development
inferredcites →https://doi.org/10.1136/bmjgh-2022-011535openalex-extracted
Improving access to medicines and beyond: the national volume-based procurement policy in China
inferredcites →https://doi.org/10.1162/0033553041502144openalex-extracted
Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry
inferredcites →https://doi.org/10.1186/s12992-022-00847-zopenalex-extracted
A systematic review of pooled procurement of medicines and vaccines: identifying elements of success
inferredcites →https://doi.org/10.1257/aer.20181169openalex-extracted
Two-Way Fixed Effects Estimators with Heterogeneous Treatment Effects
inferredcites →https://doi.org/10.1287/mnsc.1120.1680openalex-extracted
Customer-Driven Misconduct: How Competition Corrupts Business Practices
inferredcites →https://doi.org/10.1509/jmkr.2005.42.3.323openalex-extracted
Direct-to-Consumer Advertising and Drug Therapy Compliance
inferredcites →https://doi.org/10.2139/ssrn.1152391openalex-extracted
Matching for Causal Inference Without Balance Checking
inferredcites →https://doi.org/10.2139/ssrn.3940088openalex-extracted
Competitive Bidding in Drug Procurement: Evidence from China
inferredcites →https://doi.org/10.2307/2118360openalex-extracted
The Management of Innovation
inferredcites →https://doi.org/10.2307/2118402openalex-extracted
Corruption
inferredcites →https://doi.org/10.2307/2232884openalex-extracted
Dynamic R & D Competition
inferredcites →https://doi.org/10.2307/2551549openalex-extracted
Optimal Advertising Policy under Dynamic Conditions
inferredcites →https://doi.org/10.3386/w21714openalex-extracted
Prescription Drug Advertising and Drug Utilization: The Role of Medicare Part D
inferredcites →https://doi.org/10.3386/w28755openalex-extracted
Which Markets (Don't) Drive Pharmaceutical Innovation? Evidence From U.S. Medicaid Expansions
inferredcites →https://doi.org/10.3389/fphar.2023.1192423openalex-extracted
Does China’s centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model
inferredcites →https://doi.org/10.3389/fpubh.2021.809453openalex-extracted
Can the Profitability of Medical Enterprises Be Improved After Joining China's Centralized Drug Procurement? A Difference-in-Difference Design
inferredcites →https://doi.org/10.5202/rei.v1i2.17openalex-extracted
Flexible Strategies for Centralized Public Procurement
inferredcites →https://doi.org/10.5202/rei.v1i2.4openalex-extracted
Flexible Strategies for Centralized Public Procurement
inferredcites →https://doi.org/10.7916/d8r21bbjopenalex-extracted
Preemption, Leapfrogging, and Competition in Patent Races
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.